Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s

Executive Summary

Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.

You may also be interested in...



Stock Watch: Lilly, Third-Quarter Earnings And Receding Pandemic Tides

The comparison of a company’s performance during a windfall period, like one with pandemic-related sales, with a more normal period, can be uncomfortable. Even more so if the underlying business has its weaknesses.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Lilly goes head-to-head in Alzheimer’s; Roche eyes new opportunities for Lucentis; Novartis doubles down on innovation; BMS seeks growth amid generic threats; and the new head of Boehringer Ingelheim India talks to Scrip.

Biogen’s Q3 Aduhelm Sales Even Worse Than Expected

Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.  

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145300

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel